I don't follow it closely but was surprised to see it in the 1's. This was a 100 dollar stock in the boom days. I thought they had some interesting compounds (HCV, Lupus, antibodies)/technology but haven't kept up with them. Anyone follow/own, is it the debt that has killed the stock or clinical development?
Market Data 
Markets 
AI
